TY - JOUR
T1 - Lorazepam in cancer patients treated with cisplatin
T2 - A drug having antiemetic, amnesic, and anxiolytic effects
AU - Laszlo, J.
AU - Clark, R. A.
AU - Hanson, D. C.
AU - Tyson, L.
AU - Crumpler, L.
AU - Gralla, R.
PY - 1985
Y1 - 1985
N2 - There currently is no pharmacologic approach to the problem of anticipatory nausea and vomiting (ANV). Lorazepam (Ativan, Wyeth Laboratories, Philadelphia) is an interesting candidate drug if it could block the recall of the unpleasant events associated with chemotherapy, especially if it also has antiemetic properties. Since ANV is a conditioned (learned) response, it may well depend on a memory imprint of the stimulus. This pilot study was designed to use intravenous lorazepam given before and after cisplatin infusion in 32 patients, and to make detailed measurements of nausea, vomiting, recent memory, anxiety, and sedation as well as toxicity. Satisfactory responses occurred in about 70%, as rated separately both by investigator and patient. Forty-six percent did not even recall receiving chemotherapy, regardless of whether or not they vomited; 80% had no significant anxiety about chemotherapy. Adverse reactions included some cases of perceptual disturbance, urinary incontinence, diarrhea, hypotension, and one case of severe transient amnesia. No long-term adverse effects were noted.
AB - There currently is no pharmacologic approach to the problem of anticipatory nausea and vomiting (ANV). Lorazepam (Ativan, Wyeth Laboratories, Philadelphia) is an interesting candidate drug if it could block the recall of the unpleasant events associated with chemotherapy, especially if it also has antiemetic properties. Since ANV is a conditioned (learned) response, it may well depend on a memory imprint of the stimulus. This pilot study was designed to use intravenous lorazepam given before and after cisplatin infusion in 32 patients, and to make detailed measurements of nausea, vomiting, recent memory, anxiety, and sedation as well as toxicity. Satisfactory responses occurred in about 70%, as rated separately both by investigator and patient. Forty-six percent did not even recall receiving chemotherapy, regardless of whether or not they vomited; 80% had no significant anxiety about chemotherapy. Adverse reactions included some cases of perceptual disturbance, urinary incontinence, diarrhea, hypotension, and one case of severe transient amnesia. No long-term adverse effects were noted.
UR - http://www.scopus.com/inward/record.url?scp=0021879894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021879894&partnerID=8YFLogxK
U2 - 10.1200/JCO.1985.3.6.864
DO - 10.1200/JCO.1985.3.6.864
M3 - Article
C2 - 4040158
AN - SCOPUS:0021879894
SN - 0732-183X
VL - 3
SP - 864
EP - 869
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 6
ER -